Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.
V. 173 N. 2 (2022), Research article
V. 173 N. 2 (2022)

Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.: doi: 10.7417/CT.2022.2405

Research article
Pubblicato 2022-04-07
S. I. S. Fattoruso
Oncology Unit, ASL Napoli2 NORD, Frattamaggiore (Na)-Italy.
R. De Luca
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo (Pa), Italy
A. Grassadonia
Department of Medical, Oral and Biotechnological Sciences, Gabriele D’Annunzio University of Chieti, Italy
S. Evola
Cardiology Unit, UniversityHospital “P. Giaccone” (Pa), Italy
A. Salvato
Oncology Unit, ASL Napoli2 NORD, Frattamaggiore (Na), Italy
R. Addeo
Oncology Unit, ASL Napoli2 NORD, Frattamaggiore (Na)-Italy.
G. Cicero
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo (Pa)-Italy.
PDF

Parole chiave

Ca 15-3
Cyclophosphamide
Elderly woman
Metastatic breast cancer
Non-pegylated liposomal doxorubicin
Quality of life

Abstract

Background The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment.

Methods 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was  ECOG-0 and in  26 patients was  ECOG-1.

Results The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6-18.8) and median progression free survival was 5.8 months (95%CI:4.4-8.6). Hematologic toxicity with neutropenia was  the most frequent adverse event , but the treatment was well tolerated maintained a manageable cardiotoxicity.

Conclusion Non-pegylated liposomal doxorubicin may represent a valid therapeutic option in first-line for elderly patients with HER/2 negative MBC improving survival, anti-tumor response rate and decreases cardiotoxicity.

 

PDF